On September 14, Novartis AG rose 3.04% in pre-market trading, trading at approximately $141.39/share, with turnover of $4.4765 million.

On the news front, top-20 shareholder Artisan Partners publicly called for a board reorganization at Novartis. Artisan managing director David Samra urged stronger oversight of acquisitions, specifically questioning the $12 billion Avidity deal and the earlier MorphoSys acquisition, which had already been written down. The market interpreted the shareholder pressure as a positive signal for improved corporate governance.

Simultaneously, HSBC upgraded Novartis to Hold with a target price of CHF110, while RBC Capital Markets initiated coverage with a Sector Perform rating and a CHF120 target price. These upgrades provided additional support for the rebound. The stock had suffered a sharp selloff the prior week, falling over 13% after three consecutive clinical setbacks, including the Phase III failure of pelacarsen in cardiovascular outcomes, the Phase III miss of delpacibart etedesiran in myotonic dystrophy type 1, and the suspension of eight CAR-T therapy trials following patient deaths.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)